European Medicines Agency (EMA) approved Moderna’s COVID-19 vaccine for children aged 12 to 17 years on Friday.
The drug regulator of European Union (EU) informed that a study conducted among 3,732 children aged 12 to 17 years found that a comparable antibody response was seen in young adults aged 18 to 25 years vis-à-vis the effects of Spikevax vaccine.
None of the 2,163 children who were injected the Spikevax vaccine got infected with COVID-19 compared with four out of 1,073 children administered placebo. The conclusion was that efficacy of Moderna’s vaccine in those aged 12 to 17 is similar to that in adults.
The common side-effects of Spikevax vaccine in children were same as those in adults — pain and swelling at the injection site, headache, nausea, vomiting and fever.
There will be two jabs of Spikevax vaccine in the muscles of upper arm, four weeks apart.
